Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (NYSE: ABT) has declared its 403rd consecutive quarterly dividend of 55 cents per share. The dividend will be payable on Nov. 15, 2024, to shareholders of record as of Oct. 15, 2024. This announcement marks a significant milestone in Abbott's history of consistent dividend payments since 1924.
The company has demonstrated a remarkable track record of increasing its dividend payout for 52 consecutive years. This achievement has earned Abbott a place in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies that have raised their dividends annually for at least 25 consecutive years.
Abbott's 2023 Global Sustainability Report highlights progress towards its 2030 Sustainability Plan goals, focusing on expanding health access and improving lives globally. Key achievements include:
1. Introducing the world's first dual-chamber leadless pacemaker system, expanding access to millions.
2. Partnering with mAbxience to increase access to biosimilar medicines in emerging markets.
3. Expanding emergency medicine reach to 1.3 million people in Tanzania.
4. Achieving a 7% reduction in Scope 1 and 2 carbon emissions.
5. Reducing overall water use by 3% and certifying four sites with Alliance for Water Stewardship.
6. Increasing sites with zero waste to landfill to 53 globally.
7. Doubling goals for creating development and job opportunities, including STEM programs for young people.
Abbott continues to integrate sustainability principles across its business to innovate for greater access and affordability in healthcare.
Abbott has launched Lingo™, a continuous glucose monitoring system available without prescription in the U.S. for consumers interested in improving overall health and wellness. Based on Abbott's FreeStyle Libre® technology, Lingo includes a biosensor worn on the arm for up to 14 days and a mobile app that provides real-time glucose data and personal coaching insights.
Lingo aims to help users build healthy habits, retrain their metabolism, and improve well-being by tracking glucose 24/7. The system offers features such as a glucose graph, Lingo Count™ metric, food and activity logging, personal insights, and challenges. Available for adults 18+ not on insulin, Lingo comes in three options: Learn (2 weeks), Build (4 weeks), and Transform (12 weeks), priced at $49, $89, and $249 respectively.
Abbott (NYSE: ABT) has initiated the TRANSCEND study, a pivotal clinical trial evaluating the use of its deep brain stimulation (DBS) system for treatment-resistant depression (TRD). The U.S. FDA granted Abbott Breakthrough Device designation for this research. TRD affects approximately 2.8 million Americans annually, with up to a third of major depressive disorder patients experiencing treatment resistance.
DBS works like a pacemaker, sending targeted electrical pulses to specific brain areas to relieve symptoms. Previous open-label studies have shown at least a 50% sustained improvement in depression symptoms for three out of four people over two to eight years. The TRANSCEND study aims to gather evidence on the impact of neurostimulation for TRD patients who have not responded to conventional treatments.
Abbott (NYSE: ABT) has expanded its Pure Bliss™ by Similac® line of infant formulas to include organic and European-made products. The new offerings include:
- Pure Bliss Organic: USDA-certified organic formula available in powder and liquid forms
- Pure Bliss Organic with A2 Milk: USDA-certified organic formula using milk from select cows producing A2 beta-casein protein
- Pure Bliss Irish Farms: Made in Ireland with fresh milk from Irish cows
Notably, Pure Bliss Organic in 2-fluid ounce ready-to-feed bottles is the only USDA-certified organic liquid infant formula available in select U.S. retail stores. These products aim to meet diverse parental preferences for infant nutrition, offering options that are organic, European-made, and easy to digest. The expanded line is available at Amazon, Target, and Walmart.
Abbott Fund's scholarship program at the University of the Pacific is training future healthcare workers to combat diabetes in their communities. The program offers master's degrees for nurses and social workers with specialization in diabetes management, as well as certificate programs for frontline workers. Graduates like Harry Ma, Alex Marapao, and Ana Garcia are now making a difference in their hometown of Stockton, California.
The program aims to strengthen the pipeline of homegrown healthcare workers and address the growing costs of diabetes, which reached $412.9 billion in the U.S. in 2022. Scholars commit to working in the local healthcare system for at least two years after graduation, applying their specialized knowledge to improve patient care and outcomes.
Abbott has partnered with local organizations in Stockton, Calif. since 2019 to fight diabetes through a community-led management program. The initiative includes health screenings for over 1,400 residents, a 'food as medicine' program lowering HbA1c levels, and free transportation to medical appointments. Scholarships from the Abbott Fund support local healthcare students specializing in diabetes. Results indicate significant improvements in residents' health, with the program showing a decrease in HbA1c levels by 0.8% on average. The initiative demonstrates the power of community collaboration in addressing chronic diseases.
Abbott (NYSE: ABT) has announced a global partnership with Medtronic to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. This collaboration aims to improve health outcomes and reduce the burden of decision-making for people with diabetes who use intensive insulin therapy.
The partnership involves developing a CGM sensor based on Abbott's advanced Libre technology, designed exclusively for Medtronic devices. This integration will enable automatic adjustments of insulin to maintain glucose levels within the desired range. The new CGM sensor will be developed by Abbott but sold by Medtronic.
This alliance marks Abbott's fourth partnership with major insulin delivery system developers, expanding choices for people worldwide to benefit from Libre technology connectivity. The collaboration targets the estimated 11 million people globally who require multiple daily insulin injections, including those with Type 1 and Type 2 diabetes.
Cadrenal Therapeutics (Nasdaq: CVKD) has initiated discussions with Abbott (NYSE: ABT) regarding a planned pivotal study of tecarfarin in patients with recently implanted Left Ventricular Assist Devices (LVADs). Tecarfarin, a late-stage anticoagulant, received FDA Orphan Drug Designation in April 2024 for preventing blood clots and strokes in patients with implanted mechanical circulatory support devices. The collaboration focuses on improving anticoagulation treatment for HeartMate 3™ LVAD patients, currently the only LVAD available in the United States.
A recent analysis of the ARIES-HM3 study by Abbott highlighted that high-quality anticoagulation can further enhance outcomes with the HeartMate 3 LVAD. Prior clinical studies suggest that tecarfarin may provide improved anticoagulation quality, particularly in patients on multiple medications or with impaired renal function, both common in LVAD patients.
Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have launched the second year of their Innovation Incubator initiative to improve access to nutritious food and health in underserved communities. Eight community health centers across the U.S. will receive $30,000 each, along with expert guidance and training, to develop and test innovative solutions for integrating healthy food into clinical care.
The initiative aims to address food insecurity, which affects 12.8% of U.S. households, and its impact on chronic conditions like obesity, diabetes, and heart disease. Selected health centers will work on projects ranging from creating community gardens to providing customized nutrition for expectant mothers and people with chronic diseases. The results will be shared with 1,400 health centers nationwide, potentially benefiting over 31 million patients.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
